Abstract:Abstract Background and Aims Upcoming glucocorticoid (GC)-sparing treatment strategies like avacopan could potentially diminish or replace the need of GC therapy for ANCA-associated-vasculitis (AAV) in the future. Therefore, a proper assessment of GC-related morbidity in AAV is required to provide further justification of such therapies. The aim of this study was therefore to assess the incidence of common toxicities and to further investigate the effect of GC-treatment on the incidence and management of diabetes mellitus, arterial hypertension and hypercholesterolemia. Method In this single-centre-cohort-study we screened medical records for patients with a diagnosis of AAV admitted to the Robert-Bosch-hospital (RBK) in Stuttgart, Germany on a regular basis. We assessed the dosage and duration of immunosuppressive therapy used to treat AAV, as well as the incidence and therapies of arterial hypertension, diabetes mellitus and hypercholesterolemia. For this study, we observed the vasculitis time course during the acute phase (180 days) after either the initial diagnosis or relapse for each patient. Results We included 74 patients admitted to the RBK since 2004 up to the current date. Most common subtype of AAV was GPA (n = 48 patients), followed by MPA (n = 22) and EGPA (n = 4). Including relapses, a total of 127 events were observed. We followed patients for a mean time of 8 years (SD 3.9, 0.9 - 18.0 years). Mean duration of glucocorticoid therapy in total was 4.2 years (SD 3.6, 0.3-14.7 years). All of the patients received prednisolone, whereas 73% of the patients furthermore were administered methylprednisolone for induction therapy. Overall, 34% of the patients were diagnosed with diabetes before or after the diagnosis of AAV (14% pre-existing diabetes, 20% new-onset diabetes). Daily and accumulated GC-dose did not differ between patients with or without diabetes. However, there was a significant higher accumulated GC dose in patients requiring insulin-therapy for diabetes management in comparison to those with oral antidiabetics (p-value = 0.0214). 89% of the patients were treated with antihypertensive therapy (38% pre-exisiting hypertension, 51% new-onset hypertension). We found that the accumulated dose of prednisolone within the first 180 days after a vasculitis event was not significantly higher for patients with documented hypertension. However, we detected that the mean accumulated GC dose after a vasculitis event was significantly higher for the subgroup of patients in whom an escalation of antihypertensive therapy was initiated in comparison to the patients whose therapy was stable or even deescalated (p-value = 0.0001). With regard to hypercholesterolaemia, there was no statistical difference in the accumulated GC-dose during the acute course between patients requiring statin-therapy and those who did not. Conclusion GC related toxicities are common in patients with AAV. This study provides additional evidence about the incidence of treatment related harms in AAV to further promote importance of alternative reduced dose or even GC free treatment approaches. This may be relevant in detecting risk groups for whom upcoming GC-sparing treatment strategies such as avacopan are essential to reduce treatment-related harm.

Key considerations for modelling the long-term costs and benefits of treatments for ANCA-associated vasculitis

Treatment goals in ANCA-associated vasculitis: defining success in a new era

ANCA-associated vasculitis—treatment standard

Management of antineutrophil cytoplasmic antibody-associated vasculitis: a review of recent guidelines

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

[Management of ANCA-associated vasculitides]

Long-term outcome of kidney function in patients with ANCA-associated vasculitis

The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: a retrospective study

Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a systematic review

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

#4732 GLUCOCORTICOID-RELATED ADVERSE EFFECTS IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS

Update on targeted treatments for ANCA-associated vasculitis

Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis

Relapse Predictors in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons

Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies

Avacopan for the treatment of ANCA-associated vasculitis: an update

The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey

ANCA-associated Vasculitides--advances in Pathogenesis and Treatment.